依托泊苷联合地塞米松治疗HLH疗效确证:HLH-2004协作研究长期结果
HLH-2004研究纳入2004至2011年369例<18岁符合HLH-2004标准的儿童,中位随访5.2年,5年生存概率61%(95%CI 56%-67%),230例(62%)存活。与HLH-94历史数据比较,移植前死亡率由27%降至19%(P=0.064,校正年龄和性别),但差异未达统计学显著。
要点
- 符合HLH-2004标准的369例患儿中,230例(62%)存活,5年生存概率61%(95%CI 56%-67%)。
- 有家族史/遗传学确诊FHL患儿(n=168)5年生存概率59%(52%-67%),无家族史/遗传学确诊者(n=201)为64%(57%-71%)。
- 与HLH-94比较,移植前死亡率由27%降至19%(P=0.064,校正年龄和性别),未达统计学显著。
核心结论
- HLH-2004证实多数患者可经依托泊苷/地塞米松联合方案获得挽救,但前期加用CSA、鞘内治疗加用糖皮质激素及缩短至移植时间未显著改善结局。
研究设计与样本
- HLH-2004为协作研究,2004至2011年纳入369例年龄<18岁、符合HLH-2004纳入标准(8条诊断标准中满足5条、同胞患病和/或FHL致病基因分子诊断)的儿童。
主要发现
- 中位随访5.2年,369例中230例(62%)存活,5年生存概率61%(95%CI 56%-67%)。
- 有家族史/遗传学确诊FHL患儿(n=168)5年生存概率59%(52%-67%),无家族史/遗传学确诊者(n=201)为64%(57%-71%);家族性发病者(n=47)为58%(45%-75%)。
- 采用HLH-94纳入标准与历史数据比较,移植前死亡率由27%降至19%(P=0.064,校正年龄和性别),差异未达统计学显著。
- HSCT后总体5年生存概率66%,遗传学确诊FHL者为70%(63%-78%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. In the HLH-94 study, with an estimated 5-year probability of survival (pSu) of 54% (95% confidence interval, 48%-60%), systemic therapy included etoposide, dexamethasone, and, from week 9, cyclosporine A (CSA). Hematopoietic stem cell transplantation (HSCT) was indicated in patients with familial/genetic, relapsing, or severe/persistent disease. In HLH-2004, CSA was instead administered upfront, aiming to reduce pre-HSCT mortality and morbidity. From 2004 to 2011, 369 children aged <18 years fulfilled HLH-2004 inclusion criteria (5 of 8 diagnostic criteria, affected siblings, and/or molecular diagnosis in FHL-causative genes). At median follow-up of 5.2 years, 230 of 369 patients (62%) were alive (5-year pSu, 61%; 56%-67%). Five-year pSu in children with (n = 168) and without (n = 201) family history/genetically verified FHL was 59% (52%-67%) and 64% (57%-71%), respectively (familial occurrence [n = 47], 58% [45%-75%]). Comparing with historical data (HLH-94), using HLH-94 inclusion criteria, pre-HSCT mortality was nonsignificantly reduced from 27% to 19% (P = .064 adjusted for age and sex). Time from start of therapy to HSCT was shorter compared with HLH-94 (P =020 adjusted for age and sex) and reported neurological alterations at HSCT were 22% in HLH-94 and 17% in HLH-2004 (using HLH-94 inclusion criteria). Five-year pSu post-HSCT overall was 66% (verified FHL, 70% [63%-78%]). Additional analyses provided specific suggestions on potential pre-HSCT treatment improvements. HLH-2004 confirms that a majority of patients may be rescued by the etoposide/dexamethasone combination but intensification with CSA upfront, adding corticosteroids to intrathecal therapy, and reduced time to HSCT did not improve outcome significantly.
引用
- Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017. PMID: 28935695. doi:10.1182/blood-2017-06-788349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。